The United States National Institute of Health (NIH) is about to test the potency of a “monoclonal antibody (mAB),” which has been invented to prevent malaria from infecting anyone exposed to mosquito bites.
If the test proves safe and effective, it will be become a life saver for “tourists, medical workers or military personnel who travel to areas where malaria is common,” according to the Director of NHI’s National Institute of Allergy and Infectious Diseases (NIAD), Dr. Anthony S. Fauci
Dr. Fauci made the announcement and invitation for volunteers in a statement today, Monday 27 January 2020.
Fauci said in the statement that NIAD requires 73 volunteers aged between 18 and 50 and who have never suffered malaria, to volunteer for testing of mAB CIS43LS as it is exposed to humans for the first time.
The volunteers will be “exposed to malaria parasite-carrying mosquitoes under carefully controlled conditions at the Walter Reed National Military Medical Center in Bethesda.”
The research for antibodies to fight malaria infection has been propelled by the lack of highly effective, long-lasting vaccine that prevents malaria infections.
“Preventing malaria infections for several months with a single dose of monoclonal antibody also could be valuable in specific parts of Africa where malaria cases increase greatly during annual rainy seasons,” Fauci said.
For the ways in which the antibody will be administered and expectations of the scientists that are working on the experiment, here is the original announcement from NIAD.
Cover Image credits:
Creator: Thoko Chikondi; Copyright: Thoko Chikondi 2019 Information; extracted from IPTC Photo Metadata